Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + Lenalidomide in R/R DLBCL
NCT02086604Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2014
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brentuximab vedotin and lenalidomide in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Safety as measured by grade and frequency of adverse events and Maximum Tolerated Dose. Started Sep 2014; status: completed.
02
Drugs
brentuximab vedotinlenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02086604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086604.